Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by three months after accepting new 24-month clinical data and additional analyses from the company.
The submission supports a refined proposed indication focused on upper limb function, which is the primary goal of Capricor’s late-stage trial. That represents a shift from the company’s earlier attempt to secure approval for treating cardiomyopathy in Duchenne patients, which was rejected by the FDA last year. The extension gives regulators more time to consider the new evidence, but it also means investors must wait until November 22 for a decision on a therapy that has already faced significant questions about its effectiveness.
Bull Case
The most encouraging development for investors in this case is that the FDA accepted Capricor’s amendment containing the new data. The regulator classified it as a “major amendment” and extended the review period rather than rejecting the submission outright. According to Capricor, the FDA cited the high unmet medical need among Duchenne patients when accepting the amendment. Duchenne muscular dystrophy is a rare genetic disease that affects around 15,000 people in the United States, primarily boys.
The refined indication also focuses on an area where Capricor has reported positive late-stage results. The company said its trial met its primary goal by demonstrating a statistically significant benefit in upper limb function. Capricor subsequently submitted 24-month follow-up data and additional analyses intended to strengthen the evidence supporting that outcome.
Chief Executive Linda Marbán said the extended follow-up gives Capricor one of the most extensive clinical datasets assessing upper limb function in Duchenne. That description comes from management, but a longer follow-up period could help the FDA evaluate whether the reported treatment benefit persists over time. The market initially viewed the extension positively, with Reuters reporting that Capricor shares rose 15% to $7.25 following the announcement. That response suggests investors interpreted the FDA’s willingness to review the amended application as preserving a possible route to approval.
The revised strategy may also give Capricor a more focused regulatory argument. Rather than relying primarily on deramiocel’s effect on Duchenne-related heart disease, the company is now asking the FDA to consider an indication aligned with the late-stage trial’s main endpoint.
Bear Case
However, it is significant for investors to consider that the acceptance of the amendment does not mean the FDA considers the new evidence sufficient for approval. It only confirms that the regulator will review the additional material, which it classified as substantial enough to extend the deadline. Deramiocel already has a difficult regulatory history. In 2025, the FDA declined to approve it for treating cardiomyopathy in Duchenne patients, concluding that the application had not met efficacy requirements and requesting additional data.
Concerns continued after Capricor resubmitted the application. In July, an FDA advisory panel voted against the effectiveness evidence, while agency staff raised questions about changes to the company’s methods for measuring trial results. Those issues could make regulators more cautious when evaluating the latest analyses.
The refined indication also changes the central focus of the application. Although upper limb function was the trial’s primary endpoint, Capricor must demonstrate that its new data and analyses adequately support approval for that specific use. A statistically significant trial result does not automatically resolve questions about study methods, clinical relevance, or the overall strength of the evidence. The three-month extension introduces additional uncertainty as well, as Capricor had expected an FDA decision by August 22, but the new deadline is November 22.
Conclusion
The FDA’s acceptance of Capricor’s amendment keeps deramiocel’s approval prospects alive and allows the agency to consider longer-term data focused on upper limb function. For patients with limited treatment options, that review could be meaningful.
For investors, however, the regulatory decision does not come without risk, as the new data may offer Capricor a better-defined case, but the company must still overcome an earlier rejection, an unfavorable advisory-panel vote, and FDA concerns about its trial analyses.
READ NEXT: Can Eli Lilly Catch Novo Nordisk in the Oral GLP-1 Race? AND Abbott vs. Intuitive Surgical: Is Consistent Growth Better Than Premium Growth?
This article is originally published at Insider Monkey.
